Clinical Trials

At PhaseBio, the patient is at the heart of what we do. Through clinical trials, patients play an integral role in the process of evaluating whether innovative medicines are safe and effective.

In working closely with patients and the scientific and regulatory communities, PhaseBio hopes to help those who need novel and innovative therapeutic options.

We currently have a number of clinical trials underway in several cardiovascular indications, including:

REVERSE-IT (bentracimab)

If you have a question on our clinical trials, please email clinicaltrials@phasebio.com.

Expanded Access Policy

In working closely with patients and the scientific and regulatory communities, PhaseBio hopes to help those who need novel and innovative therapeutic options.

We currently have a number of clinical trials underway in several cardiovascular indications, including:

BENTRACIMAB

A unique ticagrelor reversal agent to treat or prevent major bleeding

We are currently conducting a Phase 2B trial in older (ages 50-64) and elderly (ages 65-80) subjects on dual antiplatelet therapy of ticagrelor and low-dose aspirin, as well as a Phase 3 trial evaluating bentracimab in ticagrelor-treated patients with major bleeding or to enable urgent surgery.

PB1046

A long-acting VIP analogue to control pulmonary hypertension and improve cardiac function

We are currently conducting a Phase 2B trial in pulmonary arterial hypertension (PAH), as well as a long-term, open label extension study of PB1046 in PAH subjects following completion of the VIP study.

PB1046

A long-acting VIP analogue as a treatment for hospitalized COVID-19 patients who are at high risk for rapid clinical deterioration and acute respiratory distress syndrome (ARDS)

We are currently conducting a Phase 2 trial in acute respiratory distress syndrome in patients with COVID-19.

ClinicalTrials.gov
Phase 2 VANGARD Study to Assess the Efficacy and Safety of PB1046 in Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS)

Raymond Benza, MD, professor of medicine at Temple University, College of Medicine and James Magovern chair of cardiovascular research at the Allegheny Health Network, shares the limitations of the current medicines we have to treat the PAH. He provides more information on PhaseBio’s clinical trial investigating PB1046 for the treatment of patients with PAH.

If you have a question or concern on our clinical trials, please email clinicaltrials@phasebio.com.

Expanded Access Policy